Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + ipilimumab + aspirin
- Development stage
- Phase 2
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Pembrolizumab + ipilimumab + aspirin is an investigational combination regimen consisting of two immune checkpoint inhibitors—pembrolizumab (PD-1 inhibitor) and ipilimumab (CTLA-4 inhibitor)—and high-dose oral aspirin (cyclooxygenase 1 and 2 inhibitor), evaluated in phase II clinical trials primarily for advanced or metastatic melanoma. Pembrolizumab and ipilimumab enhance antitumor immunity by blocking inhibitory pathways on T cells, enabling enhanced immune response against malignant cells. Aspirin inhibits the cyclooxygenase pathway, reducing prostaglandin E2 (PGE2) synthesis and potentially amplifying the immunomodulatory activity of checkpoint inhibitors by affecting tumor immunity and inflammation. The regimen is being studied for its capacity to improve objective response rates beyond standard immunotherapy and is associated with increased risk of immune-related adverse events, especially with high-dose aspirin[1][2][3][5][6][7].
- Brand names
- Keytruda + Yervoy + aspirin
- Other names
- pembrolizumab + ipilimumab + acetylsalicylic acid
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on pembrolizumab + ipilimumab + aspirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + ipilimumab + aspirin.